Medifast Earnings Call Maps Risky Turnaround Path
Medifast ((MED)) has held its Q4 earnings call. Read on for the main highlights of the call.
President's Day Sale - 70% Off
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Medifast’s latest earnings call struck a cautious but not hopeless tone as management balanced harsh near-term realities with some early signs that its turnaround is gaining traction. Leadership highlighted rising coach productivity, stronger field engagement and solid cash reserves, but also acknowledged steep revenue declines, a shrinking coach base and a multi-year path before profitability is restored.
Coach Productivity Shows First Signs of Recovery
Revenue per active earning coach reached $4,664 in Q4 2025, up 6.2% year over year and marking the first productivity increase since mid-2022. Management framed this as a critical leading indicator, arguing that improving productivity should eventually translate into better client acquisition and future coach growth.
Field Engagement and Leadership Metrics Improve
Coach-led product and opportunity meetings picked up meaningfully, with January activity well above last year’s levels. A double-digit share of active earning coaches reached the Executive Director rank in Q4, and retention of those leaders over the next two months was the best since 2022, signaling a healthier leadership core.
Metabolic Health Strategy Backed by Clinical Data
The company leaned heavily into a science-based “metabolic synchronization” platform to differentiate itself in a GLP-1 disrupted market. A 16-week clinical study showed a 14% reduction in visceral fat and 98% preservation of lean mass, supporting Medifast’s shift toward metabolic health and its upcoming product line built around that theme.
Restructuring Drives Major Cost Reductions
Selling, general and administrative expenses fell 31.5% to $59.9 million in Q4, led by sizable cuts in coach compensation, company-led marketing and employee realignment. Management executed a restructuring that targets over $30 million in future savings, which is already baked into its 2026 outlook and is central to the return-to-profitability plan.
Balance Sheet Remains a Key Safety Net
Despite ongoing losses, Medifast ended 2025 with $167.3 million in cash, cash equivalents and investment securities and no debt on the books. Working capital of $158.7 million gives the company notable financial flexibility to fund its transformation and new product development during what is expected to be a choppy transition period.
Guidance Reinstated but Still Shows Losses
Medifast reinstated full-year 2026 guidance, projecting revenue between $270 million and $300 million and a loss per share of $1.55 to $2.75. Management expects the new product launch to begin improving profitability in Q4 2026, with further earnings gains into 2027, positioning 2026 as a bridge year rather than a full recovery.
Revenue Suffers from Market Disruption
Fourth-quarter 2025 revenue fell 36.9% year over year to $75.1 million, reflecting materially lower sales volumes. The steep drop underscores how severely the business has been hit by industry disruption and internal transformation, and it sets a low base from which the company is trying to rebuild.
Coach Base Shrinks Sharply
Active earning coaches declined to roughly 16,100 at quarter end, down 40.6% compared with the prior year. Management linked this to the rapid adoption of GLP-1 medications and to an intentional acceleration in the exit of less productive coaches as part of a broader reconfiguration of the coach life cycle.
Gross Profit and Margin Come Under Pressure
Gross profit in Q4 dropped 40.9% year over year to $52.1 million, with gross margin sliding 470 basis points to 69.4%. The company cited lost operating leverage on fixed costs and a restructuring-related charge as the main culprits, highlighting how volume declines are magnifying pressure on profitability.
Operating and Net Losses Widen
Medifast swung to a loss from operations of $7.8 million, representing negative 10.4% of revenue compared with a small profit a year ago. The net loss reached $18.1 million, or $1.65 per diluted share, though management emphasized that excluding a large noncash tax item, the loss per share would have been $0.55.
Tax Valuation Allowance Adds One-Time Hit
The company recorded a $12.1 million noncash valuation allowance against its deferred tax assets, wiping out the quarter-end balance. This move produced a highly unusual effective tax rate of negative 183.9% and created a sizable one-time headwind to reported earnings per share that will not recur in the same form.
SG&A Mix Shifts as Leverage Declines
Even with absolute SG&A dollars down sharply, SG&A as a percentage of revenue rose by 630 basis points. Management attributed this to reduced leverage on fixed costs, higher coach event spending and restructuring charges, partly offset by lower company-led marketing, illustrating the pain of deleveraging on a smaller revenue base.
GLP-1 Adoption Remains a Major Headwind
Rapid uptake of GLP-1 drugs continues to reshape the weight-loss industry and is weighing heavily on Medifast’s model. Management estimated that around one-quarter of clients have used or are using GLP-1 therapies but also pointed to a sizable group returning after discontinuing medication, which it sees as a key target for its metabolic health offering.
Guidance Points to Gradual, Not Immediate, Improvement
For Q1 2026, Medifast guided revenue to $65 million to $80 million with a loss per share of $0.15 to $0.70, and it expects coach productivity to rise both year over year and sequentially. For full-year 2026, the company sees $270 million to $300 million in revenue, continued losses but improving trends by Q4 after its new product launch, and more than $140 million in working capital at year-end.
Medifast’s earnings call painted a picture of a business under significant short-term strain yet attempting a disciplined pivot toward a more defensible metabolic health niche. Investors will likely focus on whether rising coach productivity, cost savings and clinical differentiation can offset GLP-1 headwinds and stabilize revenue before the planned profitability inflection in late 2026.
